Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study

B. Camitta, L. Kun, M. Glicklich, H. Oechler, S. Adair, D. Pinkel

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Doxorubicin plus vincristine chemotherapy was given for 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is > 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.

Original languageEnglish (US)
Pages (from-to)1791-1794
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number10
StatePublished - Dec 29 1982

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Camitta, B., Kun, L., Glicklich, M., Oechler, H., Adair, S., & Pinkel, D. (1982). Doxorubicin-vincristine therapy for Wilms' tumor: A pilot study. Cancer Treatment Reports, 66(10), 1791-1794.